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ABSTRACT 
Triclosan is a multi-purpose biocide that is used in many personal care products, 
including antibacterial handsoaps and toothpastes. The wide usage of triclosan fosters its 
dispersal into the environment which might contribute to the ability of microorganisms 
to become resistant to triclosan in addition to certain other biocides and clinical 
antibiotics. 
The aim of this study was to evaluate whether long-term exposure of two strains 
of Staphylococcus epidermidis to subinhibitory concentrations oftriclosan would select 
for resistant mutants, and whether their ability to form polysaccharide biofilms lends to 
this resistance. This study also aimed to dete1mine whether a mutation in the triclosan 
target was responsible for resistance, and to determine whether these mutants could 
exhibit cross-resistance to chlorhexidine and clinical antibiotics. In addition, efflux 
capability was assessed as a presumable resistance mechanism. 
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PREFACE 
The figures and literature cited in this thesis were written according to the fo1mat of the 
Journal of Bacteriology, published by the American Society for Microbiology, to which it 




The Scottish physician Sir Alexander Ogston identified the bacterial genus 
Staphylococcus in 1880, as it was one of the primary causative agents associated with 
wound infections (37). Sir Alexander named Staphylococcus after he observed its 
characteristic grape-like clusters under a microscope (37). Staphylococci are Gram-
positive cocci that are non-flagellate, non-motile, non-spore forming, facultative 
anaerobes that produce the enzyme catalase (1 ). 
Staphylococcus is commonly divided into two distinct groups: those that produce 
the enzyme coagulase, and those that do not (1 ). Jacques Loeb first reported coagulase 
activity in 1904 (22). Loeb's method of observation is now referred to as the tube 
coagulase test, which led to the fmiher examination and characterization of 
Staphylococcus aureus in 1934 (22). Coagulase is an enzyme that binds to prothrombin, 
and initiates the polymerization of fibrin, which results in the coagulation of blood 
plasma (1 ). Staphylococcus aureus is a coagulase-positive organism relevant to the field 
of medicine (1 ). The medical relevance of Staphylococcus aureus is largely due to its 
multiple virulence factors including toxic shock syndrome toxin-1, alpha-toxin, emetic 
pyrogenic superantigens, and enterotoxins (I) Staphylococcus aureus was isolated in 
1884 by German scientist Anton Rosenbach (36). Rosenbach also distinguished between 
Staphylococcus aureus and Staphylococcus epidermidis by describing two pigmented 
colony types (36). The pigments led to his appropriately proposed nomenclature: 
Staphylococcus aureus so named for its golden color, and Staphylococcus a/bus for its 




Members of the genus Staphylococcus that do not produce coagulase are referred 
to as coagulase-negative staphylococci (CoNS). CoNS are often used in the food 
processing industry as sta1ier cultures for fermented food products such as fermented 
sausages (22). Such organisms include Staphylococcus xylosus, Staphylococcus carnosus, 
Staphylococcus s11cci1111s, and Staphylococcus equorum (22). 
Other CoNS are found naturally living in the mucous membranes and on the 
surfaces of warm-blooded birds and animals, including humans (21). Coagulase-negative 
staphylococci are often considered to be beneficial as they are used in the food processing 
industry, and because they exist as normal floral symbionts. However, CoNS are 
opportunistic pathogens, especially in immunocompromised, long-term hospitalized, and 
critically ill patients (22). 
Common CoNS that have the ability to produce infection in humans include 
Staphylococcus saprophyticus and Staphylococcus epidermidis. Staphylococcus 
saprophyticus is a common cause of urinary tract infections in sexually active females 
(1). Staphylococcus epidermidis, which is most often associated with medical prosthetic 
devices, is the most common CoNS of concern (1 ). Infection can occur upon implantation 
of a device by either the seeding of the device during a prior bacteremia or by gaining 
access to the lumina of catheters and shunts (1 ). 
Pathogenesis of Staphylococcus epidermidis 
Staphylococcus epidermidis, which is the most frequently isolated species of 
CoNS, is the leading cause of infections related to prosthetic medical devices ( 49). The 
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ability of Staphylococcus epidermic/is to cause infection is due to virulence factors such 
as delta-toxin (47). Staphylococcus epidermidis is also frequently able to resist the action 
of antibiotics due to its ability to form viscous extracellular polysaccharide biofilms on 
surfaces (27). Multiple factors facilitate the initial adherence of Staphylococcus 
epidermidis to prosthetic devices, including macromolecular components in body fluids 
such as blood, urine, saliva, and mucus (6). Other nonspecific physiochemical variables 
for adherence include Van der Waals forces, surface tension, temperature, and 
electrostatic interactions (12). Staphylococcus epidermidis also has surface proteins 
including SSP-1 and SSP-2, which function in the adherence of the cells onto polystyrene 
surfaces ( 46). The surface protein function is largely due to their organization into 
fimbria-like structures (46). Once adherence has occurred, the proliferation stage 
commences, where the production of extracellular polysaccharides and polysaccharide 
intercellular adhesin (PIA) is upregulated cementing the cells to each other and to the 
surface (6). PIA is a linear 13-1,6-linked glucosaminoglycan which is synthesized by 
enzymes encoded by the ica operon (33). PIA provides extra adhesion and encases the 
entire bacterial population, acting as a shield against the host defense systems and 
externally administered antimicrobial agents (33). 
A mature biofilm is comprised of several layers and reveals groups of 
microcolonies, which are separated by fluid-filled channels (33). These channels are 
thought to facilitate distribution of nutrients and oxygen throughout the biofilm in 
addition to the removal of metabolic waste (17). 
Detachment of cells from a biofilm is the combined effect of cell viability, growth 
patterns, and shear stress (51). Staphylococcus epidermidis secretes delta-toxin, which 
lyses erythrocytes in mammalian hosts, acts as a detergent during biofilm detachment 
( 47). The accessory gene regulator (agr) quorum sensing system is also thought to 
function in biofilm detachment by dowmegulating surface protein expression and 
upregulating exoenzyme and toxin expression (3 7). The agr quorum sensing system has 
been observed as being expressed only by the outer, most exposed, layers of the biofilm 
(48). 
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Clinical problems that have arisen due to the fonnation ofbiofilms on indwelling 
medical devices are largely due to the fact they are frequent inhabitants of the surface of 
human skin, mucous membranes, ear canals, and anterior nares. In the past 50 years, 
Staphylococcus epidermidis has become a significant opportunistic pathogen due to its 
ability to resist certain antibiotics, especially in hospital patients who have received 
vascular grafts, heart valves, coronary stents, and fracture-fixation implants (10). The 
ability of Staphylococcus epidermidis to resist multiple antibiotics is largely due not only 
to the ability of the organism to form biofilms, but also to the extensive use of 
antimicrobials and disinfectants, which exerts selective pressure (33). This selective 
pressure can potentially lead to the evolution of a multi-drug resistance phenotype. 
Antibiotic Resistance Mechanisms 
The ability of staphylococci to resist antibiotics continues to escalate as one of the 
major complications in medical microbiology. Misuse of antibiotics including using them 
to treat colds, flu, or other viral infections, causes the antibiotics to become less effective 
against the bacterial agents they were originally intended to treat (31 ). Less than 3% of 
Staphylococcus aureus strains were resistant to penicillin G when it was first introduced 
5 
(1). Over 90% of Staphylococcus aureus strains are now resistant to penicillin G (1). 
This phenomenon illuminates the potential for rapid bacterial evolution resulting in 
antibiotic resistance. Staphylococcus epidermidis, being an abundant inhabitant of human 
skin, is constantly exposed to multiple fmms of selection pressure such as over the 
counter antibacterial products. This form of oppo1iunity combined with its bountiful 
genetic flexibility makes Staphylococcus epidermidis the perfect contender for the 
development of resistance. As antibiotic resistance continues to emerge as one of the 
greatest public health concerns on a global scale, one of the aims of the scientific 
community is to identify factors that are essential for the virulence of pathogens (29). 
There are several known mechanisms used by bacteria to resist antibiotics. Some 
bacteria produce enzymes that alter the antibacterial agent so it can no longer bind to its 
target molecule (1 ). Some bacteria have evolved the ability to alter the molecule targeted 
by a particular antibiotic (1 ). Cetiain bacteria, namely Gram-negative organisms, alter 
porins, which leads to a decreased uptake of the drug (1). Other organisms use molecular 
efflux pumps to export antimicrobials out of the cell (1). These efflux pumps have been 
attributed to the ability of cells to eliminate more than one antibiotic (9). 
The resistance mechanisms mentioned above could be evolved independently or 
acquired on mobile genetic elements via conjugation, transduction, or transfonnation, 
which often facilitates the incorporation of multiple resistance genes into the genome or 
plasmids within the host cell ( 45). 
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Enoyl-Acyl Carrier Protein Reductase (Fahl) and Triclosan 
Antibiotics seek to inhibit pathways required for a bacterium to survive, yielding 
either a bactericidal or bacteriostatic effect. An impo1tant pathway used by 
Staphylococcus epidermidis is the assembly of fatty acids via the expression of the enoyl-
acyl carrier proteinreductase gene (Jab]) (18). The assembly of fatty acids brings 
together two-carbon units in a cyclic sequence of reactions (18). Fabl is used to catalyze 
the final step in each cycle (18). Fab 1 also plays a regulatory role in determining the rate 
of fatty acid synthesis. Inhibitors of this step in the fatty acid synthesis pathway such as 
hexachlorophene and triclosan are thus effective antibacterial agents (Fig. 1) (18). 
2-Hydroxyphenylethers make up a group of compounds exhibiting a broad 
antimicrobial activity spectrnm (7). Of these compounds, 2,4,4' -trichloro-2' -
hydroxydiphenyl ether, more commonly referred to as triclosan (Fig. 2), is the most 
potent and widely used (7). Triclosan was first introduced in 1965 and has been shown to 
be very stable, as it has the ability to resist degradation in both dilute acidic and alkaline 
solutions (50). Triclosan is a multi-purpose biocide and has been used for more than 30 
years in many personal care products, including antibacterial hand soaps, antiseptics, 
cutting boards, facial cleansers, lotions, and toothpastes (15). This wide and long-term 
use not only exposes human normal floral organisms to the biocide, but fosters the 
dispersal of the biocide into the envir01m1ent, which, as the present study indicated, might 
explain the ability of microorganisms to become less susceptible to antibiotics and 
biocides, including triclosan, via either intrinsic or acquired mechanistic adaptations upon 
exposure ( 42). 
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It was once thought the mode of action of triclosan was nonspecific cellular 
membrane disruption (18). However, it is now known triclosan works by inhibiting 
enoyl-acyl carrier protein reductase (Fabl) in a broad spectrum ofboth Gram-positive 
and Gram-negative organisms which use this enzyme in the elongation cycle ofbacterial 
fatty acid biosynthesis (13). Triclosan, which exhibits the hallmarks of a slow-binding 
inhibitor, inhibits Fabl by forming a stable, non-covalent, Fab1-NAD+-triclosan ternary 
complex, leading to complete inhibition of bacterial growth and replication (18) (Fig. 1 ). 
Triclosan Resistance 
Despite its potent mode of action, there are some bacteria that remain resistant to 
triclosan. Some of the various mechanisms of conferred triclosan resistance include: 
decreased influx/membrane pe1meability, increased target expression, the expression of 
highly efficient efflux pumps that function to rid the cell oftriclosan, target mutation, the 
production of an enoyl reductase enzyme having a low affinity for triclosan, and the 
expression of a triclosan degrading enzyme (39, 50). For example, Pseudomonas 
ae111gi11osa expresses Fabl but is still resistant to triclosan due to expression of the 
MexAB-OprM efflux system (7). 
Staphylococcus aureus usually is susceptible to triclosan. Triclosan has thus been 
used in an effort to control the spread ofmethicillin-resistant Staphylococcus aureus 
(MRSA) in hospitals (24). A study conducted in 2003 suggested the wide usage of 
triclosan would not select for triclosan resistant MRSA; however, it was found that some 
MRSA clones might not be as susceptible to triclosan as normal strains (2). Other 
laboratory studies have shown mutations infabl and their overexpression correlate to 
the decreased susceptibility of Escherichia coli and Staphylococcus aureus to triclosan 
(13). 
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A recent study showed repeated Staphylococcus aureus exposure to subinhibitory 
triclosan concentrations resulted in increased resistance to triclosan (24). Triclosan 
exposure also led to the attenuation ofbiofilm forming ability, hemolysis, DNase, and 
coagulase activities (24). These data suggest an increased triclosan resistance could also 
be associated with reduced pathogenicity (24). Latimer et. al., 2012 used a concentration 
of0.0029% triclosan, which is a concentration several orders of magnitude lower than the 
concentration used in most commercial products. The study presented in this thesis used 
triclosan concentrations up to 1.5% to simulate the actual effects of using products 
containing therapeutic concentrations of triclosan as an active ingredient. 
Correlation of Triclosan Resistance to Clinical Antibiotic Resistance 
In addition to the wide use oftriclosan selecting for resistance, one of the major 
concerns of the overuse oftriclosan is its ability to cause resistance to other antimicrobial 
agents, including traditional, clinical antibiotics. It is thought inappropriate administration 
of antibiotics can select for more generalized resistance (31 ). This rationale has been 
demonstrated in several bacterial strains including Pseudomonas ae111ginosa and 
Escherichia coli (7). It has also been demonstrated in Salmonella enterica and 
Mycobacterium smegmatis, in which resistance to triclosan has also been shown to lead 
to resistance to the antibiotic isoniazid ( 4, 7). The prevalence of Staphylococcus 
epidermidis, its constant exposure to triclosan, inherent genetic flexibility, and the 
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multiple demonstrations oftriclosan-mediated cross-resistance to traditional antibiotics 
in different organisms, suggests Staphylococcus epidermidis could demonstrate a 
profound ability to resist triclosan, which might help mediate cross-resistance to 
antibiotics with multiple modes of action. To test this rationale, the present study used six 
antibiotics to represent several of the broad classes of antibiotics, based on mode of 
action. These were ampicillin and vancomycin, which affect cell wall synthesis, 
azithromycin, which acts on the 50S ribosomal subunit to interfere with protein synthesis, 
gentamicin and tetracycline, which also interfere with protein synthesis, but by acting on 
the 30S ribosomal subunit, and ciprofloxacin, which targets DNA gyrase and 
topoisomerase IV interfering with nucleic acid synthesis. These antibiotics are chemically 
classified as B-lactams, glycopeptides, macrolides, aminoglycosides, tetracyclines, and 
fluoroquinolones respectively (1 ). 
Chlorhexidine 
N-( 4-chlorophenyl)-1-3-(6-{N-[3-( 4 chlorophenyl) 
carbamimidamidomethanimidoyl] amino} hexyl) carbamimidamidomethanimidamide, 
more commonly known as chlorhexidine, is an antimicrobial compound often used in 
such products as surgical scrnbs, topical anti-infective agents, and oral rinses (11 ). 
Chlorhexidine is effective against a broad range of Gram-positive and Gram-negative 
organisms and is thought to function by destroying the integrity of the cell membrane and 
precipitating the cytoplasm (11 ). This mechanism makes a chlorhexidine resistance 
phenotype highly unlikely; however, development of stable resistance to chlorhexidine 
has been observed in strains of Pseudomonas stutzeri after being exposed to increasing 
concentrations of the agent (44). These resistant strains have also shown reduced 
sensitivity to antibiotics and biocides such as triclosan (5). Resistance is thought to be 




This project sought to determine whether exposure of two different strains of 
Staphylococcus epidermidis to the biocide triclosan could lead to an increased minimum 
inhibitory concentration. This study also sought to detennine whether an increased 
resistance was made more efficient by the ability of the organism to form a 
polysaccharide biofilm. This project investigated whether triclosan resistance in 
Staphylococcus epidermidis could be mediated by Jab] mutation or an increased efflux 
capability. 
With respect to triclosan, this study also aimed to determine whether long-term 
exposure to subinhibitory triclosan could lead to an increased resistance to the 
disinfectant chlorhexidine or clinically administered antibiotics. 
MATERIALS AND METHODS 
Bacterial Cultures 
Two Staphylococcus epidermidis strains were donated by Dr. Greg Somerville's 
lab at the University ofNebraska. These strains are SE1457 and SE1457 l'l.ica. SE1457 
has been genetically altered to overexpress the intercellular adhesion (ica) operon, while 
the ica operon has been removed from SE1457 l'l.ica to have discemable biofilm positive 
and negative strains, respectively. 
Establishing the Triclosan Minimum Inhibitory Concentration 
Unless stated otherwise, all incubations in this work were at 37 °C. Triclosan 
stock was prepared by dissolving 0.75 g oftriclosan in 5.0 mL of95% ethanol. This is 
15% triclosan, which is l00X the normal therapeutic concentration in personal care 
products, which is 0.15%. This stock solution was diluted by adding 50 µL of the l00X 
stock to 5.0 mL oftryptic soy broth (TSB). A ten-fold serial dilution scheme was then 
used to dilute the triclosan to a series from 0.15% to 0.0000015%. Fifty microliters of 
overnight cultures of both strains of Staphylococcus epidermidis were introduced into 5.0 
mL of each of the serially diluted triclosan-containing broths. The strains were incubated 
for 24 hours. The minimum inhibitory concentration (MIC) was defined as the lowest 
concentration of triclosan in which there was no turbidity. 
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Establishing the Chlorhexidine Minimum Inhibitory Concentration 
A 20% w/v aqueous solution of chlorhexidine gluconate (Alfa Aesar, Ward Hall, 
MA) was diluted in TSB to 2.0%, which is the typical concentration used in oral rinses 
and scrnbs. A ten-fold serial dilution scheme was used to dilute the chlorhexidine to a 
series from 2.0% to 0.000002%. The serially diluted tubes were each inoculated with 50 
µL of overnight TSB cultures of either SE1457 having been passed in TSB for 70 days, 
SE1457 having been exposed to subinhibitory triclosan for 70 days, SE1457Llica having 
been passed in TSB for 70 days, or SE1457 Llica having been exposed to subinhibitory 
triclosan for 70 days. The cultures were incubated for 24 hours, and the MIC of each 
strain was defined as the lowest concentration of disinfectant at which there was no 
turbidity. 
Cell maintenance 
Once the MICs oftriclosan were established for each strain, one group of both 
strains was exposed to a subinhibitory concentration oftriclosan for 14 days, while 
another group of each strain was grown in TSB in the absence of triclosan. In this case, 
the subinhibitory concentration was 1/10 of the MIC. Each group of cells was incubated 
for 24 hours, and then 50 uL of culture were passed into 5.0 mL of the appropriate fresh 
growth medium after each 24-hour incubation period. The triclosan MI Cs were 
reevaluated at the end of every 14-day period via the serial dilution method mentioned 
previously. Whenever an MIC increase was observed, the subinhibitory concentration to 
which the cells were exposed was increased accordingly such that the cells continued to 
be exposed to a 1/10 subinhibitory concentration. 
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Frozen stocks of the unexposed cells and the triclosan exposed cells were 
prepared each time an increase in MIC was observed. To do this, a sterile 60% glycerol 
solution was prepared by diluting glycerol with deionized water. The stocks were then 
prepared by combining 750 µL of overnight culture and 250 µL of the 60% glycerol 
solution in 1.5 mL microcentrifuge tubes. The resulting stocks were frozen at -80 °C. 
Polymerase Chain Reaction 
The enoyl-acyl carrier protein reductase gene (fabl) was amplified by the 
polymerase chain reaction (PCR). Primers were designed from the sequence of 
Staphylococcus epidermidisfabl deposited in GenBank. The primers used were 
FablF (5' AGTATCGCATTTGGCGTCGCT 3') and 
FablR (5'GCGTTTTAACGGCGCTCTCGC 3'). GoTaq PCR Core System II, which 
contains the components used in the PCR, was purchased from Promega Corporation 
(Madison, WI). The following PCR components were combined in a 0.5 mL 
microcentrifuge tube: 5.0 µL of25 mM magnesium chloride solution, 10 µL of5X green 
GoTaq flexi buffer, 1.0 µL of PCR nucleotide mix, containing 10 mM of each of the 
dNTPs, 1.5 µL ofFablF primer, 1.5 µL ofFablRprimer, 0.5 µL ofGoTaqpolymerase, 
20.5 µL of nuclease-free water, and 10 µL of DNA template from Staphylococcus 
epidermidis. Template DNA was genomic DNA prepared by boiling the cultures for five 
minutes. The PCR was allowed to occur in a thermocycler with the following conditions: 
95 °C for three minutes, followed by 40 cycles of 95 °C for 45 seconds, 55 °C for one 
minute, and 72 °C for one minute. The final elongation cycle was allowed to occur at 72 
°C for 10 minutes. PCR amplification ofthefabl gene was conducted on both the 
triclosan-exposed cells and the unexposed cells. PCR product was confirmed by using 
1.5% agarose gel electrophoresis. 
DNA Sequencing and Alignment 
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The PCR products were submitted to Gene Wiz (South Plainfield, NJ) for direct 
sequencing by using the same primers as those used for the PCR. The resulting sequences 
were translated to peptide sequences by using EMBOSS Transeq Sequence Translation 
tools from EMBL-EBI. Both the DNA sequences and the peptide sequences were aligned 
by using EMBOSS Needle Pairwise Sequence Alignment tools from EMBL-EBI. 
Kirby-Bauer Disc Diffusion Assay 
The Kirby-Bauer disc diffusion assay was used to evaluate any differences in 
antibiotic resistance that might have occurred in both the unexposed and the triclosan 
exposed strains. The assay was conducted according to the manufacturer's instructions 
(BD, Franklin Lakes, NJ). Briefly, the bacterial strains were incubated in tubes containing 
TSB for 24 hours. The strains were then standardized in a spectrophotometer by using a 
0.5 McFarland Standard at a wavelength of 595 nm. Bacterial lawns were then streaked 
onto Mueller-Hinton agar by using sterile cotton swabs so as to completely cover the 
Petri plates. Antibiotic-embedded filter paper discs were placed on the Petri plates by 
using an antibiotic disc dispenser. The antibiotics used were: ampicillin (10 µg), 
azithromycin (15 µg), ciprofloxacin (5 µg), gentamicin (10 µg), tetracycline (30 µg), and 




The Etest was conducted on the triclosan-exposed and unexposed bacteria by 
following the instrnctions provided by the manufacturer (bioMerieux, Durham, NC). 
Briefly, the bacterial strains were incubated in tubes containing TSB for 24 hours. The 
strains were then standardized in a spectrophotometer by using a 0.5 McFarland Standard 
at a wavelength of 595 nm. Bacterial lawns were streaked onto Mueller Hinton agar, by 
using sterile cotton swabs. One E-strip was used per Petri plate and the results were read 
according to the Etest reading guide found in the Etest pack insert provided by the 
manufacturer. Antibiotics used in the Etest were the same as those used in the Kirby-
Bauer disc diffusion assay. 
Efflux Assay 
A quantitative efflux-mediated multi-drug resistance assay was used according to 
Martins et. al., (2010) to detem1ine whether subinhibitory triclosan exposure influenced 
the overexpression of efflux systems. Ethidium bromide (Sigma-Aldrich, St. Louis, MO) 
was prepared in distilled water at a stock concentration of 50 mg/Land was protected 
from light by storing it in bottles wrapped in aluminum foil. Tryptic soy agar plates 
containing the following concentrations of ethidium bromide were prepared: 0.0, 0.5, 1.0, 
1.5, 2.0, and 2.5 mg/L. Twenty groups of cells, representing each of the five increases in 
triclosan MIC and their corresponding unexposed strains, were grown for 24 hours in 5.0 
mL ofTSB and standardized to an optical density of0.6 at a 600 nm wavelength. 
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Pseudomonas aeruginosa (ATCC 24783) and Escherichia coli (ATCC 25922) were 
used as positive and negative controls, respectively, for efflux ability. 
Bacterial samples were streaked with a sterile swab in a cartwheel pattern on tryptic soy 
agar (TSA) plates containing various concentrations of ethidium bromide. The plates 
were incubated for 18 hours, and observed under ultraviolet light and photographed. The 
minimal concentration of ethidium bromide that led to fluorescence was recorded. 
RESULTS AND DISCUSSION 
Effects of Triclosan Exposure 
In this study, passage of Staphylococcus epidermidis SE1457 and SE1457 l'.ica in 
subinhibitory concentrations oftriclosan for 70 days resulted in an increase in the MIC of 
triclosan. For both strains, the initial triclosan MIC was 0.00015% and the final MIC was 
1.5%. Hence, after 70 days of exposure to a 1/10-subinhibitory concentration of triclosan, 
the exposed cells became 10,000 times more resistant to triclosan than their 
corresponding unexposed strains (Fig. 3). The triclosan MIC increased at the same rate in 
both biofihn-positive and biofilm-negative strains. This suggested that the presence of an 
ica operon does not contribute to an increased ability to resist triclosan. The 
concentration of triclosan found in most personal care products is 0.15% meaning 
subinhibitory exposure resulted in resistance to the typical therapeutic dose of triclosan. 
Chlorhexidine 
The minimum inhibitory concentration of chlorhexidine was 0.00002% on all 
strains of Staphylococcus epidermic/is used in this study. Thus, neither the ability to form 
a biofilm nor an increased ability to resist triclosan, regardless of extended exposure time, 
had any effect on the ability of the organism to resist chlorhexidine. These results further 
support the rationale that an increased resistance to chlorhexidine is unlikely due to the 
fact chlorhexidine is thought to have multiple targets (11 ). 
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DNA Sequencing and Alignment 
One proposed mechanism of triclosan resistance in Staphylococcus aureus is 
changes in the penneability of the cell wall could prevent triclosan from reaching its 
target site (43). Other studies have shown that/ab] mutation can lead to the development 
of triclosan resistance in organisms such as Escherichia coli and Staphylococcus aureus 
(16). It has also been demonstrated that afabl mutation is required for triclosan 
resistance and that the altered/ab] must be overexpressed at levels three- to fivefold 
higher than the level of expression in triclosan-sensitive strains (13). 
In this study, sequencing of the Jab] gene, amplified from the triclosan resistant 
Staphylococcus epidermic/is SE1457 strain and the corresponding unexposed strain, 
showed a point mutation at position 235 in the triclosan exposed strain (Fig. 4). This 
mutation codes for an amino acid change from alanine to valine at position 95 in the 
protein sequence (Fig. 5). The Ala-95 in the unexposed strain has been shown to be part 
of the active site region of the Fab1-NAD+-triclosan ternary complex (19). The 4-chloro 
substituent oftriclosan accepts a hydrogen bond from the amide backbone of Ala-95 (19). 
These data suggested afabl mutation could lead to the development oftriclosan 
resistance in Staphylococcus epidennidis as a result of long-tenn subinhibitory triclosan 
exposure. 
The difference between alanine and valine is that they contain a methyl side chain 
and an isopropyl side chain respectively. This indicates that the isopropyl side chain in 
valine blocks the ability of the 4-chloro substituent oftriclosan from accepting the 
hydrogen bond from the amino acid backbone. This could interfere with the Fabl-NAD+-
triclosan ternary complex, thereby preventing the triclosan from functioning to inhibit 
bacterial fatty acid elongation. 
Kirby-Bauer Disc Diffusion Assay and Etest (Ampicillin) 
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In addition to triclosan exposure leading to an increased triclosan MIC, a series of 
Kirby-Bauer disc diffusion assays showed that cells, having evolved the ability to resist 
triclosan, also evolved an increased resistance to ampicillin whereas the unexposed 
strains did not. Etests confirmed the results of the Kirby-Bauer assays. 
The ampicillin zone of inhibition increased from 25 mm to 30 mm in the 
unexposed SE1457 strain between 0 days and 70 days of passage (Fig. 6). The MIC 
increased from 0.016 µg/mL to 0.5 µg/mL (Fig. 7). The changes in the unexposed 
SE1457 strain was most likely due to a random error in the standardization of the cells. 
The ampicillin zone of inhibition decreased in diameter from 25 mm to 6 mm in the 
triclosan exposed SE1457 strain between 0 days and 70 days oftriclosan exposure (Fig. 
6). The MIC increased from 0.016 µg/mL to 1.0 µg/mL (Fig. 7). According to the Zone 
Diameter Interpretive Chart from BD, staphylococci are considered to be resistant to 
ampicillin if the zone diameter around the ampicillin impregnated disc is <S28 mm; hence, 
the triclosan-exposed SE1457 strains with triclosan MICs of0.15% and 1.5% both 
evolved resistance to ampicillin. 
The ampicillin zone of inhibition increased in diameter from 25 mm to 30 mm in 
the unexposed SE1457L'lica strain between 0 days and 70 days of passage (Fig. 6). The 
MIC increased from 0.016 µg/mL to 0.023 µg/mL (Fig. 7). These changes were most 
likely due to a random error in the standardization of the cells. The ampicillin zone of 
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inhibition decreased in diameter from 25 mm to 6 mm in the triclosan exposed 
SE1457/'l.ica strain between 0 days and 70 days ofsubinhibitorytriclosan exposure (Fig. 
6). The MIC increased from 0.016 µg/mL to 0.75 µg/mL (Fig. 7). Hence the triclosan 
exposed SE1457 /'l.ica strains with triclosan MI Cs of 0.15% and 1.5% both evolved 
resistance to ampicillin. 
Ampicillin is known to interfere with cell wall synthesis by binding to 
penicillin-binding proteins inside the cell wall (34). A recent study showed that the 
exposure of Staphylococcus aureus to sub lethal concentrations of penicillin caused two 
cell wall proteins to shift from the peripheral wall to the septum, which was most likely 
due to an antibiotic mediated increase of free anchoring sites at the septum (52). In a 
similar manner, it is possible triclosan exposure could caused the shifting of the 
penicillin-binding proteins, therefore accounting for this ampicillin resistance. 
Kirby-Bauer Disc Diffusion Assay and Etest (Tetracycline) 
In addition to triclosan exposure leading to an increased triclosan MIC and 
ampicillin resistance, a series of Kirby-Bauer disc diffusion assays showed that cells, 
having evolved the ability to resist triclosan, also evolved an increased resistance to 
tetracycline whereas the unexposed strains did not. Etests confirmed the results of the 
Kirby-Bauer assays. 
The tetracycline zone of inhibition decreased in diameter from 30 mm to 26 mm 
in the unexposed SE1457 strain between 0 days and 70 days of passage (Fig. 8). The MIC 
decreased from 0.5 µg/mL to 0.094 µg/mL (Fig. 9). These changes were most likely due 
to random errorin the standardization of the cells. The tetracycline zone of inhibition 
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decreased in diameter from 30 mm to 10 mm in the triclosan exposed SE1457 strain 
between 0 days and 70 days of subinhibitory triclosan exposure (Fig. 8). The MIC 
increased from 0.5 ug/mL to 32 µg/mL (Fig. 9). According to the Zone Diameter Chart 
from BD, staphylococci are considered to be resistant to tetracycline if the zone diameter 
around the tetracycline impregnated disc is <14 mm, hence the triclosan exposed SE1457 
strains with triclosan MICs of0.15% and 1.5% both evolved resistance to tetracycline. 
There were no changes in the tetracycline zones of inhibition in the unexposed 
SE1457 l'iica strain between 0 days and 70 days of passage (Fig. 8). The MIC decreased 
from 0.5 µg/mL to 0.125 µg/mL (Fig. 9). This change was most likely due to random 
error in the standardization of the cells. The tetracycline zone of inhibition decreased in 
diameter from 30 mm to 7 mm in the triclosan exposed SE1457 l'iica strain between 0 
days and 70 days of subinhibitory triclosan exposure (Fig. 8). The MIC increased from 
0.5 µg/mL to 96 µg/mL (Fig. 9). Hence, the triclosan exposed SE1457 l'iica strains with 
triclosan MICs of0.15% and 1.5% both evolved resistance to tetracycline. 
Tetracyclines inhibit the synthesis of protein by binding to the 30S ribosomal 
subunit and blocking the attachment of aminoacyl-tRNA to the acceptor site of the 
mRNA ribosome complex, thus preventing the introduction of new amino acids to the 
nascent polypeptide chain (1 ). 
Two tetracycline resistance mechanisms have been identified in staphylococci. 
They are the acquisition plasmids carrying tetK and tetL genes, which result in active 
efflux, and tetM or tetO determinants carried on either the chromosome or transposons, 
which mediate ribosomal protection (41). MGE mediated resistance is unlikely due to the 
fact these experiments were carried out in pure culture in a closed system. A more likely 
resistance mechanism is the production of ribosomal protection proteins due to a 
chromosomal mutation. Possibly the cell wall has been altered in a way that has 
decreased its pe1meability. 
Kirby-Bauer Assay and Etest (Azithromycin, Gentamicin, and Vancomycin) 
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With respect to resistance, there was no difference in the zones of inhibition or 
MI Cs of azithromycin, gentamicin, or vancomycin on either the triclosan exposed cells or 
the unexposed cells (Fig. 10 to 13). These data suggest long-term exposure to 
subinhibitory triclosan does not influence an increased resistance to these antibiotics. 
Kirby-Bauer Disc Diffusion Assay and Etest (Ciprofloxacin) 
The unexposed strain of SE1457 i'.ica displayed an increased resistance to 
ciprofloxacin after being passed in TSB for 70 days. The results ofa Kirby-Bauer disc 
diffusion assay showed a decrease in the diameter of zone of inhibition around the disc 
impregnated with ciprofloxacin from 30 mm to 15 mm (Fig. 10). The MIC increased 
from 0.064 µg/mL to 3.0 ug/mL (Fig. 11). According to the Zone Diameter Interpretive 
Chart from BD, staphylococci are considered to be resistant to ciprofloxacin if the zone 
diameter around the ciprofloxacin impregnated disc is :Sl 5 mm, hence the unexposed 
SE1457i'.ica strain of Staphylococcus epidermic/is evolved resistance to ciprofloxacin in 
the absence of selection pressure. This is likely dne to a copying error during DNA 
replication. None of the other strains exhibited resistance to ciprofloxacin. 
There are two broad mechanisms of fluoroquinolone resistance, which occur as a 
result of chromosomal mutation (20). The mechanisms are alterations that limit the 
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permeation of the drug to the target and alterations in the target enzymes of the drug 
(20). In Gram-positive organisms, the target enzyme is topoisomerase IV (35). Although 
plasmid-mediated ciprofloxacin resistance has been observed, the data presented in this 
thesis suggested a chromosomal mutation was the most likely mechanism for resistance 
since the strains in this study were grown in pure culture. The data also shed light on the 
inherent genetic flexibility of Staphylococcus epidermidis. 
Efflux Assay 
The efflux-assay uses ethidium bromide, which is a universal efflux pump 
substrate (30). Ethidium bromide functions by binding with DNA and intercalating 
between its hydrophobic base pairs. This intercalation causes the DNA to stretch, 
removing water molecules from the ethidium cation. The resulting distortion of the 
double helix interferes with DNA replication, transcription, and DNA repair. This 
dehydration resulted in an increased fluorescence of the ethidium and the cell. The assay 
is based on the rationale that there is a maximum ethidium bromide concentration that 
can be effectively extruded by cells (30). Any concentration greater than this maximum 
will be retained by the cell and will lead to the detection of fluorescence when exposed to 
ultraviolet light (30). The smallest concentration of ethidium bromide that leads to 
fluorescence is the highest concentration of ethidium bromide that the bacteria can 
exclude (30). 
In addition to providing a method of ranking bacterial strains according to efflux 
capability, this assay also allows for the observation of ethidium bromide resistance. 
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In this study, the assays showed no evidence of an increased efflux capability and the 
bacterial strains were, therefore, not quantitatively ranked. The assay did, however, show 
a correlation between increased triclosan MIC and the ability of Staphylococcus 
epidermidis to grow in increasing concentrations of ethidium bromide (Fig. 14 to 17). 
All of the unexposed SE1457 strains were inhibited by 2.0 mg/L of ethidium 
bromide (Fig. 14). The triclosan exposed SE1457 strains, having been exposed to 
subinhibitory concentrations oftriclosan for 56 days and 70 days, grew in 2.5 mg/L of 
ethidium bromide (Fig. 15). All of the unexposed SE 14571"ica strains were inhibited by 
2.0 mg/L of ethidium bromide (Fig. 16). The triclosan exposed strains of SE14571"ica, 
having been exposed to subinhibitory triclosan concentrations for 42 days, 56 days, and 
70 days, grew in 2.5 mg/L of ethidium bromide (Fig. 17). All of the strains that grew in 
2.5 mg/L of ethidium bromide demonstrated growth in 4.0 mg/L of ethidium bromide 
(figures not shown). 
At physiological ionic strength, ethidium is very sensitive to the composition and 
sequence of polymeric nucleic acids (26). Ethidium has a 100-fold higher affinity to poly 
d(AT)-poly d(AT) as compared to poly d(A)-poly d(T) (26). It also exhibits a preference 
for the alternating purine-pyrimidine tract of poly d(GC)-poly d(CG) as compared to poly 
d(G)-poly d(C) (26). Additionally, ethidium exhibits a 10-fold higher affinity to poly 
d(G)-d(C) over poly d(A)-d(T) (26). Luedtke et. al., (2003) and the data from this thesis 
suggest there might have been cln·omosomal mutations profound enough to lower the 
binding affinity of ethidium bromide to the DNA of the bacterial strains exposed to 
higher concentrations oftriclosan, thereby decreasing the susceptibility of those strains to 
the ethidium bromide. 
CONCLUSIONS 
A study conducted in 1990 in which 12 populations of Escherichia coli were 
allowed to evolve for 2,000 generations showed an increase of about 37% in mean fitness 
(25). Eighteen thousand generations later, two of those populations were examined for 
the parallel evolution of gene-expression profiles when compared to the original ancestor 
population (8). The expression of 59 genes changed significantly in both populations in 
the same direction relative to the ancestor (8). This profusion of change, despite the lack 
of selection pressure, substantiates the rationale that selection pressure might lead to a 
pattern of parallel evolution even more expeditious than demonstrated in this study. 
The fact that two triclosan-resistant strains of Staphylococcus epidermidis
exhibited resistance to ampicillin and tetracycline as well as a decreased susceptibility to 
ethidium bromide, despite each of these antibacterial agents having different modes of 
action, could be indicative of several phenomena. 
One potential phenomenon is a mechanism leading to an increased cell wall 
thickness relative to increased selection pressure. This phenomenon has been observed in 
association with vancomycin resistance in Staphylococcus epidermic/is (14). Another 
potential explanation is triclosan exposure caused diminished cell wall permeability, 
which could be the result of multiple factors, including the shifting of cell wall proteins, 
which has been shown to occur in Staphylococcus aureus in association with sublethal 
ampicillin exposure (52). Mutation in thefabl gene was most likely the cause oftriclosan 
resistance, and some other cln·omosomal mutation is most likely the cause of resistance to 
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the other antibacterial agents since all of the experiments in this study were carried out 
in pure culture. 
This demonstration ofa 10,000-fold increase in triclosan resistance in 
Staphylococcus epidermidis over 70 days, due to the application of selection pressure, 
demonstrates the antimicrobial resistance problem associated with the overuse and 
misuse of antibacterial agents. The results also provide evidence that distribution of over-
the-counter antimicrobials into the environment can induce resistance to that particular 
antimicrobial in addition to ce1iain clinical antibiotics. This thesis supported the rationale 
that triclosan as well as other disinfectants should only be used circumspectly where clear 
health benefits can be discerned (24). 
Further studies should continue to investigate, identify, and understand other 
potential antibiotic resistance mechanisms. It is also necessary to understand the link 
between triclosan resistance and this newly acquired multi-drug resistance phenotype. 
Several proposed resistance mechanisms have been discussed; however, it is also possible 
that resistances mechanisms that have not yet been reported are the causes of this multi-
drug resistance phenotype. 
The relatively recent antibiotic-as-beneficial-signal hypothesis suggests 
antibiotics in nature evolved as a communication method between unrelated microbial 
species, but, if introduced to a bacterial population at a high enough concentration, can 
cause death (40). Work in the lab of Julian Davies over the last 15 years has indicated 
antibiotics made by microbes perfo1m multiple functions and that the molecules are more 
often a means of communication than of inhibition (32). 
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The microbial detection of low concentrations of antibiotics might be 
interpreted as a warning for fnture increased concentrations, which could allow the 
organism to respond in a manner that reduces susceptibility ( 40). Pseudomonas 
aeruginosa, for example, fmms a biofilm as a response to subinhibitory tetracycline 
concentrations, thereby reducing its exposure to future antibiotics ( 40). This study shows 
Staphylococcus epidermidis has a similar inherent ability to respond to triclosan, thereby 
initiating the observed change in the Fabl sequence. 
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FIG. 1. The triclosan mode of action is to target enoyl-acyl carrier protein 
reductase (Fab 1 ), the final enzyme in the fatty acid elongation cycle, by using 
NADH to reduce the double bond ofFabl (Adapted from Patel et. al., 2008). 
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FIG. 2. Molecular structure of 2,4,4' -trichloro-2' -hydroxydiphenyl ether 
(triclosan) (From Margaretha et. al., 2001), 
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FIG. 3. MIC oftriclosan on (A) unexposed SE1457 compared to triclosan-
exposed SE1457, and (B) unexposed SE1457 L\.ica compared to triclosan-exposed 
SE1457 L\.ica. 
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Query 44 AGGTGCTAAACTGGTATTTACATATCGTAAAGAACGCAGTCGTAAAGAAT 93 
I I I I I I I I I I I I I I I I I I I I I I I I 11111111111111111111111111 
Sbjct 351 AGGTGCTAAACTGGTATTTACATATCGTAAAGAACGCAGTCGTAAAGAAT 400 
Query 94 'l'AGAGAAATTA'l"l'AGAACAAT1'AAATCAATCTGAACATCA'l'CTCTATGAA 143 
11111111111111111111111111111111111111111111111111 
Sbjct 4 0 1 TAGAGAAA'l"l'A'l''l' AGAACAA'l"l'AAA'l'Cfu'\'l'C'l'GAACATCA'l'C'l'C'l'A'l'<iAA 450 
Query 144 ATTGATGTGCAGAATGATGAGGATATCATTAATGGTTTTTCTCAAATCGG 193 
11111111111111111 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct 451 ATTGATGTGCAGAATGATGAGGATATCATTAATGGTTTTTCTCAAATCGG 500 
Query 19 4 AAAAGJ\TGTAGGCCAGATTGATGGTGTTTJ\TCACTCAATC1TAT'rTGCCA 243 
Sbjct 501 illUU!J,H!!~HlUllUlJ.U.1H!JlHMl!~ JJ.H!!~l 550 
Query 244 ATATGGAAGATTTACGAGGTCGATT~TCAGAAACATCTCGCGAAGGTTTC 293 
I I I I I I 111111111111 I I I I I II I I I I I I 1111111111111111 I 11 
Sbjct 5 51 ATJ\TGGru\GA'rTTACGAGGTCGATTTTCAGAAACJ\TCTCGCGAI\GG'rT'l'C 600 
Quory 294 •r·rACTTGCACAAG/IAJ\TTAG'r'l'CATATTCAC'l"fACTC'rCG'rAGCTCA1'GA 343 
I 111111111111111111111111111111111111! I I 111111111 I 
Sbjct 60 l TTACTTGCACMGAAA'l'TAGTTCATJ\TTCACTTACTCTCG'fAGC'l'CATGA 650 
Query 34 4 AGCCAAru\MCTTATGCCTGAAGGTGGAAG'l'ATTG'fTGCGACGACT'fA1'A 393 
I 1111111111111111111111111111111111111111111111111 
Sbjct 651 AGCCMAAAAC'.l"fA1'GCCTGAAGG'.1'GGAAm'AT'.l'GT'fGCGACGACT'l'ATA 700 
Query 394 'rTGGTGG'rGAGGCAGCAG'ITCAAAACTM'AATGTTATGGGTGTAGC'l'AAA 443 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1111111111111111111 
Sbjct 7 0 l TTGGTGGTGAGGCAGCMTTCAAAAC'rl,TM'l'GT'l'ATGGG'rG'l'AGC'rAAA 750 
Query 44 4 GCAAG'l"fTAGAGGCGAA'rGTTAAATATTTAGCTTTAGACTTAGG'rGAAGA 493 
11111111111111111111111111111111111111111111111111 
Sbjct 7 51 GCAAGTTTAGAGGCGAA1'GTTMATATT'l'AGGTTTAGACTTAGGTGAAGA 800 
Query 4 9 4 TAATAT'rCGTGTCMTGCTATT'l'CTGCAGGGCCAATTCGTACTTTAAG'IG 543 
111111111111111111111111111111111111 l I I I I I I I I I I I I I 
Sbjct 80 l TAA'IATTCGTGTCAATGC'l'ATTTC'IGCAGGGCCAATTCGTACTT'fAAGTG 850 
FIG. 4. Nucleotide alignment from EMBOSS for SE1457 fabl from the unexposed strain 
(Sbjct) and triclosan-exposed strain after 70 days of exposure (Query) generated from the 
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1111111 I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111 
143 YSLTLVAHEAKKLMPllGGSIVATTYIGGEAAVQNYNVMGVAKASLEANVK 
558 YLALDLGEDNIRVNAISAGPIRTLSAKGVGGFNTILKEIJlARAP 











FIG. 5. Partial protein alignment results from blastx for SE1457 Fabl sequences from the 
unexposed strain (Sbjct) and triclosan-exposed strain after 70 days of exposure (Query). 
The mutation of alanine (A) to valine (V) at position 95 is indicated by a circle. 

















Kirby-Bauer Assay (Ampicillin): SE1457LUca 
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FIG. 6. Ampicillin zone of inhibition of (A) unexposed SE1457 compared to 
triclosan-exposed SE1457, and (B) unexposed SE1457i'.ica compared to 
triclosan-exposed SE1457 i'.ica. 
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FIG. 7. MIC ofampicillin on (A) unexposed SE1457 compared to 
triclosan-exposed SE1457, and (B) unexposed SE1457tica compared to triclosan-
exposed SE1457 tica as determine by Etests. 
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Kirby-Bauer Assay (Tetracycline): 
SEl 457 Liica 
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FIG. 8. Tetracycline zone of inhibition of(A) unexposed SE1457 compared to 
triclosan-exposed SE1457, and (B) unexposed SE1457i'.ica compared to 











































FIG. 9. MIC of tetracycline on (A) unexposed SE1457 compared to 
triclosan-exposed SE1457, and (B) Unexposed SE1457i'iica compared to 
triclosan-exposed SE 1457 i'iica as determined by Etests. 
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Kirby-Bauer Assay (Azithromycin & 
Ciprofloxacin): SE1457 
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FIG. 10. Azithromycin and ciprofloxacin zones of inhibition of (A) unexposed 
SE1457 compared to triclosan-exposed SE1457, and (B) unexposed SE1457~ica 
compared to triclosan-exposed SE1457~ica. 
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FIG. 11. MIC of azithromycin and ciprofloxacin on (A) unexposed SEl 457 
compared to triclosan-exposed SE1457, and (B) unexposed SE1457~ica 
compared to triclosan-exposed SE1457 ~ica as dete1mined by Etests. 
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l{irby-Bauer Assay (Gentamicin & 
Vancomycin): SE1457 
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l{irby-Bauer Assay (Gentamicin & 
Vancomycin): SE1457 Liica 
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FIG. 12. Gentamicin and vancomycin zones of inhibition of(A) unexposed 
SE1457 compared to triclosan-exposed SE1457, and (B) unexposed SE1457Liica 
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FIG. 13. MIC of gentamicin and vancomycin on (A) unexposed SE1457 
compared to triclosan-exposed SE1457, and (B) unexposed SE1457 /1.ica 
compared to triclosan-exposed SE1457 /1.ica as determined by Etests. 
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0.0 mg/L EtBr 0.5 mg/L EtBr 1.0 1ng/L EtBr 
1.5 1ng/L EtBr 2.0 mg/L EtBr 2.5 mg/L EtBr 
FIG. 14. Evaluation of efflux activity of unexposed SE1457 strains. In a 
counterclockwise fashion, the strains are Pseudomonas aeruginosa (PA), 
Staphylococcus epidermidis passed in TSB for 14, 28, 42, 56, and 70 days, and 
Escherichia coli (EC). 
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0.0 mg/L EtBr 0.5 1ng/L EtBr 1.0 1ng/L EtBr 
1.5 mg/LEtBr 2.0 mg/L EtBr 2.5 mg/L EtBr 
FIG. 15. Evaluation of efflux activity oftriclosan-exposed SE1457 strains. In a 
counterclockwise fashion, the strains are Pseudomonas ae111gi11osa (PA), 
Staphylococcus epidermidis exposed to subinhibitory triclosan for 14, 28, 42, 56, and 70 
days, and Escherichia coli (EC). 
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0.0 mg/L EtBr 0.5 mg/L EtBr 1.0 mg/LEtBr 
1.5 mg/L EtBr 2.0 mg/L EtBr 2.5 mg/L EtBr 
FIG. 16. Evaluation of efflux activity of unexposed SE1457i'.ica. In a counterclockwise 
fashion, the strains are Pseudomonas aeruginosa (PA), Staphylococcus epidermidis 
passed in TSB for 14, 28, 42, 56, and 70 days, and Escherichia coli (EC). 
51 
0.0 mg/L EtBr 0.5 mg/L EtBr l.0mg/LEtBr 
1.5 mg/L EtBr 2.0 mg/L EtBr 2.5 mg/L EtBr 
FIG. 17. Evaluation of efflux activity oftriclosan-exposed SE1457~ica strains. In a 
counterclockwise fashion, the strains are Pseudomonas ae111ginosa (PA), Staphylococcus 
epidermic/is exposed to subinhibitory triclosan concentrations for 14, 28, 42, 56, and 70 
days, and Escherichia coli (EC). 
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Appendix A: Molecular structures of the cell wall inhibitor antibiotics, (A) ampicillin, 
which is a semisynthetic penicillin thought to function by inhibiting the final step in 
bacterial cell wall synthesis leading to the lyses of the cell, and (B) vancomycin, which is 
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Appendix B: Molecular structures of (A) ciprofloxacin, which is a fluoroquinolone that 
inhibits bacterial nucleic acid synthesis by inhibiting bacterial DNA-gyrase and 
topoisomerase IV in Gram-negative and Gram-positive organisms respectively, and (B) 
azitluomycin, which is a macrolide antibiotic that binds to 23S rRNA in the 50S subunit 





N Nl l ~NH 
B 
CH 3 I 
el 
113 C 
HO OH OH ,,, 
11 CH 3 
,, .. H3C1,, '•,,,,,, 
H C ____.._' \' 0 '·· 
"""•o~ 3 ' ' 
0 ··· .. , /CH, ,, 0 N 







Appendix C: Molecular structures of (A) gentamicin, which is an aminoglycoside that 
directly inhibits protein synthesis by binding to the 30S ribosomal subunit, and causing 
the misreading of mRNA, and (B) tetracycline, which binds to the 30S ribosomal subunit, 
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Appendix D: Molecular structure of ethidium bromide, which is a universal efflux pump 
substrate, and can also interfere with DNA replication (30). 
Appendix E: Molecular structure of chlorhexidine, which is a disinfectant and topical 
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